FIELD: pharmacology.
SUBSTANCE: an application method of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepin or its pharmaceutically acceptable salts for the prevention of cancer metastasis is proposed. Herewith the cancer cells express a voltage-sensitive sodium channel Nav1.5. Also, a pharmaceutical composition for the same purpose and application method of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepin or its pharmaceutically acceptable salts for the prevention of cancer metastasis in patients having one or more cancer cells which express a voltage-sensitive sodium channel Nav1.5, are proposed.
EFFECT: said compound reduces the metastatic current in mammary adenocarcinoma cells and does not interfere with the normal function of the heart even at high doses.
11 cl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TETRAHYDROPYRIDO[3,4-B]INDOLE DERIVATIVES USEFUL IN TREATMENT OF CANCER | 2014 |
|
RU2664109C2 |
| METHOD OF PRODUCING N-[3-[(2-METHOXYPHENYL)SULFANYL]-2-METHYLPROPYL]-3,4-DIHYDRO-2H-1,5- BENZOXATHIEPIN-3-AMINE | 2007 |
|
RU2414464C9 |
| COMPOUNDS FOR TREATING CANCER | 2015 |
|
RU2733393C2 |
| COMPOUNDS AND COMPOSITIONS FOR STABILISATION OF HYPOXIA INDUCED FACTOR-2 ALPHA AS METHOD OF CANCER MEDICAL TREATMENT | 2012 |
|
RU2602498C2 |
| USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | 2018 |
|
RU2780354C2 |
| COMPOUNDS FOR TREATMENT OF CANCER | 2015 |
|
RU2805949C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2013 |
|
RU2699546C2 |
| CANCER TREATMENT METHODS | 2019 |
|
RU2811406C2 |
| 4-OXO-3,4-DIHYDROQUINAZOLINONE COMPOUNDS FOR TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2021 |
|
RU2814662C1 |
| PROPOSED 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | 2022 |
|
RU2826000C1 |
